Madis Prink

https://www.etis.ee/CV/Madis_Prink/est
10.12.1985
53471235

Teenistuskäik

Töökohad ja ametid
01.01.2008–...   
Vähiuuringute Tehnoloogia Arenduskeskus, tehnik
2014–2016   
Lääne-Tallinna Keskhaigla AS, Turundusjuht (1,00)
2012–2014   
dxlabs OÜ, Juhatuse liige (1,00)
2011–2014   
Protobios OÜ, (1,00)

Kvalifikatsioon

Teaduskraadid
Madis Prink, magistrikraad, 2009, (juh) Kaia Palm, RNAi and peptide based drug development (RNAi ja peptiitsete ravimite arendus), Tallinna Tehnikaülikool, Matemaatika-loodusteaduskond, Geenitehnoloogia instituut, Molekulaarbioloogia õppetool.
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.1. Biomeditsiin; CERCS KLASSIFIKAATOR: B726 Kliiniline bioloogia
 
 
Lisainfo
2015 Medical services export, Marketingi Instituut
2014 ISO 17025 quality assessor, Estonian Accreditation Center
2014 Validation of analytical methods, Testing Center of University of Tartu
2013 ISO 9001 internal audit, Bureau Veritas
2013 ISO 9001, Bureau Veritas
2013 SMEST2: Positive aspects of standardization for SME-s, Estonian Center for Standardization
2013 Export of products and services, Estonian Chamber for Commerce and Industry
2012 Export management, AS Äripäeva koolitused
2011 Strategic management of sustainable entrepreneurship, Tallinn University of Technology 2011 Development, Entrepreneurship, Technology and Innovation, Tallinn University of Technology
2009 Team building, BDA consulting

Lõppenud projektid

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2014
Tints, K; Prink, M; Neuman, T; Palm, K. (2014). LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells. International Journal of Molecular Sciences, 15 (4), 5680−5698.
18.04.2018

Madis Prink

https://www.etis.ee/CV/Madis_Prink/eng
10.12.1985
53471235

Career

Institutions and positions
01.01.2008–...   
Competence Centre for Cancer Research, technician
2014–2016   
West-Tallinn Central Hospital, Head of Marketing and Public Relations (1,00)
2012–2014   
dxlabs LLC, Board member (1,00)
2011–2014   
Protobios LLC, Quality manager (1,00)

Qualifications

Academic degrees
Madis Prink, Master's Degree, 2009, (sup) Kaia Palm, RNAi and peptide based drug development, Tallinn University of Technology Faculty of Science, Department of Gene Technology, Chair of Molecular Biology.
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.1. Biomedicine; CERCS CLASSIFICATION: B726 Clinical biology
 
 
Additional information
2015 Medical services export, Marketingi Instituut
2014 ISO 17025 quality assessor, Estonian Accreditation Center
2014 Validation of analytical methods, Testing Center of University of Tartu
2013 ISO 9001 internal audit, Bureau Veritas
2013 ISO 9001, Bureau Veritas
2013 SMEST2: Positive aspects of standardization for SME-s, Estonian Center for Standardization
2013 Export of products and services, Estonian Chamber for Commerce and Industry
2012 Export management, AS Äripäeva koolitused
2011 Strategic management of sustainable entrepreneurship, Tallinn University of Technology 2011 Development, Entrepreneurship, Technology and Innovation, Tallinn University of Technology
2009 Team building, BDA consulting

Completed projects

Publications

Category
Year
Publication
 
1.1.
2014
Tints, K; Prink, M; Neuman, T; Palm, K. (2014). LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells. International Journal of Molecular Sciences, 15 (4), 5680−5698.
18.04.2018
Detailne otsing
  • Leitud 2 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
MUUMODEST-037291 (037291)Modular devices for ultrahigh-throughput and small-volume transfection04.04.200704.04.2010Kaia PalmProtobios OÜ183 446,56 EUR
MUUEU27549Peptiidsete ravimikandidaatide rakendusuuring01.01.200831.12.2009Kaia PalmProtobios OÜ317 909,32 EUR